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Summary Carcinoembryonic antigen (CEA) is an oncofetal antigen whose function in the progression of
colorectal carcinoma remains unclear although recent studies suggest it participates in homotypic cellular
adhesion. We have previously shown that 40 fig of CEA injected intravenously into athymic nude mice
enhances experimental metastasis in liver and lung by two human colorectal carcinoma cell lines that are
injected intrasplenically 30 min later. The metastatic potential of another three moderately to highly metastatic
colorectal carcinoma cell lines and of one weakly metastatic line has now been analysed in this model. CEA
pretreatment only enhanced colony formation by cell lines that were weakly metastatic in untreated nude mice;
it did not affect experimental metastasis by highly metastatic lines. CEA pretreatment enhanced the retention
of 25I Idudr-labelled weakly metastatic tumour cells within the liver and lungs 4 h after intrasplenic injection
but not the retention of highly metastatic tumour cells or inert latex beads. A significant correlation existed
between the formation of experimental metastases and the early retention of tumour cells within the liver after
intrasplenic injection. Aggregation did not appear to be important for retention in liver because CEA did not
aggregate colorectal carcinoma cells in vitro. Also CEA did not alter natural host effector cell function in a
cytolysis assay in vitro. We suggest that CEA facilitates liver colonisation by three of eight human colorectal
carcinomas in athymic nude mice by increasing the hepatic retention of tumour cells. The potential
mechanisms by which CEA may increase the retention of tumour cells in the liver are discussed.
Carcinoembryonic antigen (CEA) is a member of the
immunoglobulin supergene family (Williams & Barklay,
1988) and may participate in intercellular recognition and
attachment (Benchimol et al., 1989). CEA- and nonspecific
cross-reacting antigen (NCA) expressing carcinoma cells and
CHO cell transfectants from homotypic aggregates in vitro
(Benchimol et al., 1989; Oikawa et al., 1989). Recent work by
Zhou et al. (1990), suggests that while CEA- and NCA-
expressing transfectants preferentially form homotypic agg-
regates they will also make heterotypic aggregates with each
other, but not with transfectants expressing other immuno-
globulin family members such as the neural cell adhesion
molecule (NCAM). These observations may be important to
the study of metastasis because CEA may promote
homotypic aggregation of carcinoma cells to each other or
heterotypic aggregation to host cells displaying other CEA
family members (such as granulocytes (Berling et al., 1990)).
Both types of aggregates may then be retained at sites of
meta-stasis and increase the number of malignant cells
available for invasion. CEA may also promote colonisation
through a heterotypic adhesion mechanism if the CEA on the
membranes of carcinoma cells binds to CEA receptors at
sites of metastasis.
The liver and lung are the most frequent sites of metastasis
of colorectal carcinoma in patients (Spratt & Spjut, 1967;
Murray et al., 1975). Kupffer cells in the liver and alveolar
macrophages in the lung are known to bind CEA in the
circulation through specialised receptors (Toth et al., 1982;
1985). Human (Toth et al., 1989) and rodent (Toth et al.,
1985) Kupffer cells endocytose CEA, remove sialic acid, and
secrete asialo CEA which is immediately bound and
metabolised by the hepatocyte. In contrast, alveolar macro-
phages endocytose CEA and degrade it without releasing
immunoreactive epitopes (Toth et al., 1989a). Hepatocytes do
not bind CEA but rapidly clear asialo CEA through the
asialoglycoprotein receptor (Thomas & Summers, 1978). As a
result, CEA may occupy receptors on the membranes of
Kupffer cells and alveolar macrophages while asialo CEA is
displayed on hepatocytes. The CEA on carcinoma cells also
has the potential to bind directly to receptors on Kupffer
cells or alveolar macrophages and act as intercellular
adhesion molecules. Alternatively, if CEA is a homophilic
binding protein, then colorectal carcinoma cells traversing
the hepatic or pulmonary microcirculation may bind to CEA
occupying receptors on Kupffer cells or alveolar macro-
phages.
Elevated serum levels of CEA at the time of definitive
surgery for localised colorectal carcinoma is associated fre-
quently with the subsequent appearance of distant metastases
(Wanebo et al., 1978; Goslin et al., 1980). While the CEA
level may represent secretion by microscopic or subclinical
metastases, our hypothesis is that CEA in the circulation
may 'condition' the host to facilitate the implantation and
growth of tumours. Our approach to this problem was to
inject CEA systemically into nude mice that later receive an
intrasplenic injection of human colorectal carcinoma cells.
We have previously reported that CEA pretreatment in-
creased the number of experimental liver (Hostetter et al.,
1990a and b) and lung (Wagner et al., 1990) metastases
produced by two weakly metastatic colorectal carcinoma cell
lines. We now extend these findings and provide more in-
formation about the specificity and the similarity of the
model to the clinical situation. We also present evidence that
CEA may mediate its effect by increasing the number of
tumour cells retained in the liver, possibly through a cell
adhesion mechanism.
Materials and methods
Proteins
The CEA used in these experiments is human 180- to 200-
kDa CEA, purified from a single colorectal carcinoma
hepatic metastases, as previously described (Byrn et al.,
1985). The preparation was characterised by sodium dodecyl
sulfate polyacrylamide gel electrophoresis, high pressure
liquid chromatography analysis and activity in commercial
CEA assay systems. It's behaviour in experimental animals is
known (Byrn et al., 1985). Asialo CEA was produced by
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neuraminidase digestion of CEA (Bessell et al., 1975). Bovine
serum albumin (BSA) and alpha, acid glycoprotein were
purchased from Sigma Chemical Co. St. Louis, MO.
Animals
Six- to eight-week-old BALB/c AnNU athymic nude mice
were obtained from the Harlan Sprague-Dawley Laboratories
(Indianapolis, IN). Mice had free access to feed and water
and were housed five mice/cage under specific-pathogen-free
conditions. The mice were age and sex matched for each
experiment. Mice were quarantined for 1 week prior to use in
experiments. All experimental protocols were approved by
the institutional animal care and usage committee of the New
England Deaconess Hospital.
Cell lines
KM-12c was established at the M.D. Anderson Cancer
Center as previously described (Morikawa et al., 1988a,b)
while MIP-101 was derived by Niles et al., (1987). Clone A
was obtained from Dr D.L. Dexter (Dexter et al., 1979). The
other colon or rectal carcinoma cell lines (HT-29, CCL 188,
and CCL 235) as well as the lymphoma YAC-l were
obtained from the American Type Culture Collection, Rock-
ville, MD. Cells were cultured in RPMI 1640 (MIP-lOl, CCL
235, and YAC-l) or Dulbecco's Modified Eagle's Medium
(all other lines) supplemented with 10% heat inactivated fetal
calf serum, 100 unitsml-' penicillin, 100ligml-' strepto-
mycin, and nonessential amino acids. All culture reagents
were obtained from Sigma Chemical Co., St. Louis, MO.
Immunoperoxidase studies
Tissues were fixed in 10% formal saline, embedded in
paraffin, and processed for routine staining with hematoxylin
and eosin. Immunoperoxidase staining using a rabbit poly-
clonal antibody to CEA (DAKO, Accurate Chemical and
Scientific Co., Westbury, NY, absorbed with human spleen
powder to remove anti-NCA activity) was carried out by a
standard 3-step technique using swine-anti-rabbit immuno-
globulin as the bridging antisera and peroxidase-anti-
peroxidase followed by antigen localisation with diamino-
benzidene. Slides were counterstained with hematoxylin.
Metastatic potential assay
The potential of human colorectal carcinoma cell lines to
form experimental metastases was examined in nude mice
after intrasplenic injection of viable tumour cells as
previously described (Hostetter et al., 1990b). In brief, groups
of five mice were injected in the dorsal tail vein with bovine
serum albumin (BSA, 200figml-'), al acid glycoprotein
(a,AGP, 200 jg ml'), asialo CEA (200pgml-'), or CEA
(25-200jigml-') in 0.2ml of Hanks' balanced salt solution
(HBSS) or with HBSS alone. Thirty min later, the mice were
anesthetised and given intrasplenic injections of 2 x 106
tumour cells through a laparotomy. Mice that received KM-
12c cells were injected with 5 x 105 cells as described
previously (Hostetter et al., 1990b). All groups were sacrificed
when mice in any group became moribund. Autopsies were
performed and the presence of colonies in the liver, lungs,
and other sites was determined by macroscopic inspection
and confirmed histologically. Tumour burden was assessed
by the criteria of Giavazzi et al. (1986).
Hepatic retention assay
Groups of three nude mice were pretreated with HBSS or
CEA as described for the metastatic potential assay and then
injected intrasplenically with 2 x 106 tumour cells that had
been prelabelled with '25I-IdUdR as previously described by
Hostetter et al. (1990b), sacrificed 4 h later, and the 1251
content of livers, spleens, intestines, and kidneys measured by
gamma counting. Results are presented as the mean ± s.e.m.
of the percent of the injected cells in the liver at 4 h. In some
experiments, 0.1Oml of 0.6% 3.0 j carboxylated polystyrene
beads (Polysciences, Inc., Warrington, PA) covalently
coupled with '251-labelled albumin in HBSS were injected in
place of cells into CEA- or HBSS-pretreated mice.
Cell aggregation
The effect of soluble CEA on the aggregation of colorectal
carcinoma cells was analysed by incubating 5 x 105 cells with
either 0.5 or 1.0 jig ml-' of CEA in culture medium for
90 min on a rotating shaker at 25°C. Control cells were
incubated in medium alone. Aliquots were transferred to a
hemocytometer and both the number of total cells and single
cells (i.e. cells not touched by another cell) were counted.
Results are expressed as percent single cells and represent the
inverse of the number of cells that form aggregates.
Cytotoxicity assays
The effect of CEA on NK and macrophage function was
tested in an in vitro spleen cell cytotoxicity assay. Spleen cells
were harvested from athymic nude or normal BALB/c mice
and erythrocytes lysed as previously described (Jessup et al.,
1981). Spleen cells were either used fresh or incubated with 1,
0.5, or Ojigml-' CEA in RPMI 1640 with 10% heat in-
activated foetal calf serum at 37°C for 20 h prior to use in
the assay. Tumour cells were prelabelled with 5'Cr by
incubating trypsinised tumour cells (5 x 106 per ml) with
400 iLCi of sodium chromate (Na2CrO4, specific activity
450mCimg-', New England Nuclear, Boston, MA) for 4h
at 37°C and washed three times with medium. Tumour cells
(5 x 104) and spleen cells (2 x 106) were added to individual
wells in a 96-well microtiter plate (Corning) in a final volume
of 0.2 ml of RPMI 1640-10% foetal calf serum. Maximum
release was determined by adding 50jl of 1% sodium
dodecylsulfate to the microtiter wells. Assays were performed
in quadruplicate. After 4 or 20 h at 37°C, microtiter plates
were centrifuged at 400g for 5 min and 50jl of the super-
natant collected and counted. Results are expressed as
mean ± s.e.m. of the percent of all cell counts released.
Statistics
Results are expressed as mean ± s.e.m. Differences among
groups of means were tested by one-way analysis of variance
(ANOVA). When ANOVA demonstrated that means within
an experiment were significantly different from one another,
significance between individual group means was tested with
either the Fisher PSLD or Dunnett t test with a significance
level of 5%. The incidence of experimental metastasis was
compared by chi-square analysis. All calculations were per-
formed on a Macintosh SE microcomputer using Statview
SE + Graphics (Abacus Concepts, Inc. Berkeley, CA).
Results
Hepatic distribution ofCEA in nude mice andpatients
We first analysed whether the distribution of CEA in the
livers of athymic nude mice after an intravenous injection of
CEA was similar to that found in the livers of patients with
elevated serum CEA levels. Indirect immunoperoxidase stain-
ing with a polyclonal antibody to CEA was peformed on
formalin-fixed liver tissue from 11 patients whose liver metas-
tasis had been resected, of these four patients had positive
CEA staining in the uninvolved liver. Figure 1 shows the
immunoperoxidase staining from one of these patients whose
circulating CEA level was 105 ngml-'. CEA was regionally
distributed in normal liver 3 cm or more away from metas-
tasis and was identified in both Kupffer cells and hepatocytes
(Figure Ia).
The immunohistochemical distribution of CEA in the
livers of nude mice within an hour of injection was similar to466 J.M. JESSUP et al.
a
b
Figure 1 Distribution of CEA in human a, or mouse b, liver. 40jig of CEA in 0.2 ml of HBSS was injected intravenously into
groups of athymic nude mice that were sacrificed 4 h later. Human liver was taken from the uninvolved liver more than 1 cm away
from a colon carcinoma metastasis in a patient whose serum CEA level was 105 ng ml-'. CEA was identified by indirect
immunoperoxidase with a polyclonal antiserum using a PAP technique with diaminobenzidine to localise antigen and counters-
tained with hematoxylin. The mouse and human livers have similar distributions of CEA and Kupffer cells contain CEA (100 x ).
that in the liver of the patients. CEA was distributed in the
periportal regions in mouse liver in both Kupffer cells and
hepatocytes.
CEA could only be identified in or associated with Kupffer
cells or hepatocytes, not with molecules in the space of Disse.
Four h after injection, CEA was detected by immuno-
peroxidase staining in nude mouse Kupffer cells but not
hepatocytes (Figure 1). The clearance of CEA from the
circulation of the nude mouse is biphasic with a concentra-
tion of approximately 400 ng ml-' CEA in the serum 4 h
after intravenous injection of 40fg of CEA and only
12 ng ml-' at 24 h. Hepatic uptake of serum CEA results in a
concentration of approximately 75 ng mg-' of protein in the
liver 4 h after CEA injection. CEA content of liver was
measured by immuno-assay of saline-extracted liver tissue.
Twenty h after injection, CEA was neither detectable by
immunoassay of liver extracts nor observed in Kupffer cells
by immunoperoxidase staining (data not shown). The dist-
ribution of CEA in the nude mouse liver 1-4 h after the
injection of CEA is grossly similar to that of the patient
whose serum CEA level is approximately 100 ngml-'.
The specificity ofCEA-mediated enhancement ofliver
colonisation by KM-12c
The specificity of the effect of CEA on experimental meta-
stasis was defined next. Previous studies showed that injec-
tion of 5jig or less of CEA failed to stimulate KM-12c to
produce liver colonies while approximately 50% of the mice
develop liver colonies when nude mice are pretreated with 10
to 40 jg of CEA injected intravenously followed by an intra-
splenic injection of 5 x 105 tumour cells 30 min later (Hostet-
ter et al., 1990b). Since a pretreatment dose of 40jig assured
enhancement of metastasis, this dose was used in all
experiments. Nude mice pretreated with 40fig of a,AGP,
asialo CEA, or BSA intravenously did not produce more
experimental metastases by KM-12c than in HBSS-treated
nude mice (Table I). Since asialo CEA also failed to enhance
the metastasis of MIP-101 (Wagner et al., 1990), CEA must
be in its native glycosylated state to enhance experimental
metastasis.CEA EFFECT ON METASTASIS 467
Table I Specificity of the enhancement of experimental metastasis
of the KM-12c colorectal carcinoma by CEA pretreatment
Mice with P<vs
Pretreatment mets Total mice % CEA
None 1 35 3 0.001
HBSS 1 45 2 0.001
BSA 0 5 0 0.05
ml acid glycoprotein 0 9 0 0.001
asialoCEA 1 9 11 0.05
CEA 19 39 49
Groups of nude mice were injected in the dorsal tail vein with
40 Lg of the following proteins in 0.2ml of HBSS (CEA, al acid
glycoprotein, or BSA) or 0.2 ml of HBSS alone (HBSS) or left
untreated (None). 30 min later mice received 5 x I05 viable KM-12c
cells injected intrasplenically as described in Materials and methods.
The results are expressed as the number of mice with one or more
histologically confirmed metastases in the liver divided by the total
number of mice in the experiments (% of mice with metastases) and
represent the cumulative results of seven consecutive experiments. P
values determined by chi-square analysis and compared to the CEA
group.
CEA-mediated enhancement ofliver colonisation by other
colorectal carcinoma cell lines
The effect of CEA upon experimental liver metastasis was
assessed in a new set of four colorectal carcinoma cell lines
(Clone A, HT-29, CCL 235, and CCL 188) as well as new
experiments with MIP-101. In all experiments, 40 jig of CEA
in 0.2 ml HBSS was injected intravenously into groups of
5-8 nude mice 30min prior to the intrasplenic injection of
carcinoma cells while control mice received either HBSS or
were not pretreated. All mice received 2 x 106 tumour cells.
The weakly metastatic carcinoma Clone A produced liver
colonies in 32% of CEA pretreated nude mice which was
significantly more than the 8% incidence in untreated or the
none in HBSS pretreated nude mice (Table II). The incidence
of experimental hepatic metastases was not affected for MIP-
101 or the other colorectal carcinoma cell lines (Table II).
However, CEA pretreatment did increase the incidence of
lung metastases in nude mice that received MIP-101 or Clone
A cells (Table III). Two of four lung metastases from Clone
A cells and five of seven from MIP-101 cells) occurred
without microscopic evidence of liver colonisation on
autopsy (Table II). When the data from prior experiments
are included (Hostetter et al., 1990b), CEA pretreatment
significantly increased experimental lung and liver metastasis
after intrasplenic injection in three weakly metastatic human
colorectal carcinoma cell lines (KM-12c, MIP-101, and Clone
A) but did not increase experimental metastasis by either a
nonmetastatic cell line (HC 2998) or by moderately (CCL
188) or highly metastatic cell lines (CCL 235, HT-29, or
mHC 1410) (Table III).
Table III Summary ofeffect of CEA pretreatment on production of
liver and lung experimental metastases after intrasplenic injection of
human colorectal carcinomas into nude mice
Pretreatment
Cell line None HBSS CEA P< (vs HBSS)
KM-12c 3 (35) 2 (45) 48 (39) 0.001
MIP-101 5 (20) 0 (16) 44 (16) 0.001
Clone A 8 (12) 0 (18) 42 (19) 0.001
HC 2998a 0 (12) 0 (8) 0 (10) NS
mHC 1410a 100 (15) 100 (10) 90 (10) NS
CCL 235 60 (10) 88 (9) 75 (8) NS
CCL 188 36 (11) 40 (10) 40 (10) NS
HT-29 90 (10) 100 (10) 80 (10) NS
Results are presented as % of mice with liver or lung metastases
(total number of mice receiving an intrasplenic injection of tumour
cells). Treatments are as described for Table II. Each cell line was
tested in two or more experiments. aThese data are from Hostetter et
al., 1990b.
CEA does not inhibit host effector cell cytolytic activity
CEA may enhance experimental metastasis by inhibiting the
activity of potentially cytotoxic or cytostatic natural host
cells. We tested this possibility by incubating spleen cells
from mice, the organ through which the tumour cells pass to
reach the liver in the experimental metastasis model, with
CEA and then assessing whether CEA altered cytolysis in
either a short or long term assay. Spleen cells from
immunocompetent mice had natural host cell lytic activity at
4 and 20 h because YAC-l cells were lysed at both times
(Table IV). CEA did not decrease the lysis of YAC-1. Both
KM-12c and MIP-101 were relatively resistant to lysis by
these spleen cells. Spleen cells from athymic nude mice were
not affected by CEA, but produced less lysis at 4 and 20 h of
YAC-1 cells and no lysis of MIP-101 or KM-12c (data not
shown). Also spleen cells from athymic nude mice pretreated
with CEA were not more cytotoxic than spleen cells from
untreated nude mice (data not shown). These data suggest
that (1) our nude mice contain low levels of NK and other
natural host effector cells, (2) CEA does not inhibit host
effector cell function in vitro, and (3) CEA does not modify
NK or other host effector cell function in vitro.
CEA enhances the early retention ofcarcinoma cells
We tested whether the effect of CEA on metastasis was
associated with an increase in the number of tumour cells in
the liver 4 h after intrasplenic injection. Tumour cells from
one highly metastatic (CCL 188) and two weakly metastatic
lines (MIP-101 and Clone A) were prelabelled with 1251-
IdUdR and injected intrasplenically into nude mice that had
received a systemic injection of either 40,ug CEA or HBSS
Table II Enhancement of the experimental hepatic metastasis of human colorectal carcinoma cell lines by CEA
No pretreatment HBSS CEA
Mice w/ Total tumour Mice w/ Total tumour Mice w/ Total tumour
Tumour CEAa DOS" liver Metsc burdend liver mets burden liver mets burden P<
Clone A 0 60 1/12 (8) 0 x 11,11 0/18 (0) 0 x 18 6/19 (32) 0 x 11,0* x 2, 0.001
II x 4,II*,III*
MIP-101 0 65 1/20 (5) 0 x 19,JI 0/16 (0) 0 x 16 2/16 (13) 0 x 9 NS
0* x 5,1,11*
CCL 235 65 80 5/10 (50) 0 x 4,0*, 8/9 (88) 0,11 x 7, 5/8 (63) 0,0,0*, NS
II x 4,I1* II* II x 4,11*
CCL 188 97 33 4/11 (36) 0 x 7, 4/10 (40) 0 x 6,11 x 2, 4/40 (40) 0 x 5,II, NS
II x 4 111,1I* III x 2,IV
HT-29 300 50 9/10 (90) 0,11 x 9 10/10 (100) II x 9,111 8/10 (80) 0 x 2, NS
II x 7,111
'CEA production is measured by enzyme immunoassay of the spent medium and expressed as ng CEA/106 cells/day. bDOS (day of sacrifice) is
the day that mice were sacrificed for autopsy and is less than 90 if mice within a group became moribund. cThe number of mice with one or
more metastases in the liver divided by the total number ofmice in the experiments (mice w/mets) and expressed as the percentage ofmice with
metastases (% mets). dTumour burden in the liver is based on the grading system of Giavazzi et al. (22). eGroups of nude mice were injected in
the dorsal tail vein with 40iLg of CEA in 0.2 ml of HBSS (CEA) or 0.2 ml of HBSS alone (HBSS) or not pretreated (None) and 30min later
mice received viable tumour cells injected intrasplenically. Mice were sacrificed 90 days later unless they became moribund. Experimental
metastases were confirmed by histology. Experimental metastases were noted in the lungs of those mice marked with an asterisk. P values
determined by Chi square on CEA vs the None control.468 J.M. JESSUP et al.
Table IV The effect of CEA on natural host effector cells in an in vitro cytotoxicity assay
% release at 4 h % release at 20 h
Control CEA (lag ml-I)b Control CEA 9jig ml-1)b
Tumour Releasea 0 0.5 1.0 Releasea 0 0.5 1.0
YAC-1 6.1 ± 0.5 10.4 ± 0.4 10.5 ± 0.4 10.1 ± 0.3 16.8 + 0.6 29.2 ± 1.0 29.4 ± 1.7 33.6 + 1.1
KM-12c 4.2±0.1 4.0±0.2 4.2±0.2 4.1±0.1 9.0±0.2 8.9±0.4 9.4±0.3 9.5±0.3
MIP-101 6.5±0.3 6.7±0.3 6.8±0.2 6.9±0.2 21.4±0.8 21.7±0.8 21.8±0.5 22.0±0.6
aControl release is the spontaneous release and is the per cent of 5"Cr released by labelled tumour cells in the absence
of spleen cells. bSpleen cells were harvested from BALB/c mice and cocultured for 4 or 20 h with tumour cells that had
been prelabelled with 5"Cr at an effector:target ratio of40:1 at 37C with the indicated amount ofCEA in the incubation
medium. Assays were performed in quadruplicate. Results are expressed as Mean ± s.e.m. of the percentage of label
released by tumour cells. Means ± s.e.m. in bold print are significantly different from the spontaneous release control by
ANOVA and Scheffe F test at P<0.001.
Table V Retention of human colorectal carcinoma cells in the livers and other organs of nude
mice pretreated with CEA intravenously
% Injected tumour cells in each organ at 4 h
Liver Lung Spleen
Tumour CEA HBSS CEA HBSS CEA HBSS
MIP-101 61±2 27±7a 0.9±0.2 0.40.1b 6±1 6±2
Clone A 67±7 29+8' 0.4±0.1 0.3±0.1 4±1 2±1
CCL 188 43±5 47±5 0.3±0.1 0.4±0.1 10±2 10±1
2 x 106 carcinoma cells that had been prelabelled with '251-IdUdR were injected
intrasplenically into groups of three athymic nude mice 30 min after the intravenous injection of
either 40lag of CEA in 0.2 ml of HBSS or 0.20 ml of HBSS alone, as described in Materials and
methods. Results are Mean ± s.e.m. of the per cent of injected cells in organs at 4 h. ap<0.0I
and 'p<0.05 between CEA pretreated and HBSS Controls as determined by two-tailed upaired
Student t test.
30 min earlier. The mice were sacrificed 4 h later and the
livers, lungs, and other organs counted for radioactivity. The
livers of mice that received HBSS contained more CCL 188
cells than Clone A or MIP-101 cells 4 h after injection (Table
V). In contrast, CEA pretreatment significantly increased the
number of MIP-101 and Clone A cells in liver but did not
effect the retention of CCL 188 cells (Table V). In fact, there
were more MIP-101 or Clone A cells in the livers of CEA-
pretreated mice than in either group of mice that received
CCL 188 cells. There was no significant difference in the
'a a)
01)
cn U0
co 0)
0
distribution of tumour cells from any of the lines of the
kidneys, spleen, or intestine (Table V and data not shown).
There was also a significant doubling in the per cent of
MIP-101 cells in the lungs of CEA pretreated mice compared
to control mice, although the retention of Clone A and CCL
188 cells in the lungs was not effected by CEA pretreatment
(Table V).
The effect of CEA pretreatment on tumour cell retention in
the liver may be a nonspecific mechanical effect that retains
tumour cells in the liver after they initially arrest in the
hepatic sinusoid. To test this we injected '25I-albumin-labelled
2.81p microspheres intrasplenically into mice that were
crI e)
a1)
E
C._
Time (hours)
Figure 2 Effect of CEA pretreatment on the retention of micro-
beads in the liver and other organs. '25I-labelled 2.81s beads were
injected into groups of 3 -10 athymic nude mice that had received
40 jig of CEA in 0.2 ml of HBSS or HBSS alone. Mice were
sacrificed at different times and their organs collected and
radioactivity counted. Values represent means ± s.e.m. of the per
cent of injected dose of beads in the organ at the time of sacrifice.
(0), (-), and (-) the percentage of beads in the livers, lungs,
and kidneys, respectively, of HBSS pretreated mice and (*), (O),
and (0) the percentage of beads in the livers, lungs, and kidneys,
respectively, of CEA pretreated mice. The amount of radioac-
tivity in the kidneys is similar to the amount of 0.3 ml of blood
and in the gastrointestinal tract.
KM-12c CEA
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MIP-101 CEA-o
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CCL 188 HBSS
tA CEA
0 20 40 60 80
% Cells in liver
Figure 3 Relationship between retention of colorectal carcinoma
cells within the livers of nude mice and the incidence of experi-
mental metastasis. '25I-IdUdR prelabelled carcinoma cells were
injected intrasplenically into groups of three nude mice that were
either pretreated with CEA or HBSS and the percentage of
tumour cells present in the liver 4 h later calculated as described
in 'Materials and methods'. This percentage was then plotted
against the per cent of mice that developed experimental metas-
tases for each cell line that received either CEA or HBSS. The
cell lines are moderately (CCL-188), weakly (KM-12c, MIP-101,
Clone A) or nonmetastatic (HC 2998), and all (0) are included
in the regression equation whose characteristics are: %
Mets = 0.899 x % Cells- 1 1.2, R = 0.89, P<0.001. Data for %
Cells in liver for KM-12c and HC 2998 are in ref. (Hostetter et
al., 1990b) while the incidence of metastases are from Table III.CEA EFFECT ON METASTASIS 469
pretreated with either 40 tLg of CEA or HBSS and then
examined their distribution in the liver and other organs up
to 6 h later. There was no difference in the number of
microspheres in the liver up to 6 h after intrasplenic injection
(Figure 2). There was a small percentage of radioactivity that
accumulated in the lungs, blood, and other organs that may
represent particles that are released from the liver after an
initial trapping in the liver (Figure 2). Clearly, CEA pretreat-
ment does not alter the mechanical trapping of inert beads in
the liver. Thus, the ability of CEA pretreatment to double
the number of weakly metastatic tumour cells persisting in
the liver 4 h after intrasplenic injection is the result of a more
specific biological interaction among the tumour cells, hepatic
cells, and CEA.
The importance of the number of cells in the liver a few
hours after entry into the liver is underscored by comparing
the percentage of cells in the liver at 4 h to the incidence of
experimental liver and lung metastases. Indeed, when the
results of our earlier studies (Hostetter et al., 1990b) are
included, there is a linear relationship between the formation
of experimental metastases and the percentage of tumour
cells in the liver 4 h after intrasplenic injection (Figure 3).
The effect of CEA upon the retention of tumour cells is lost
within 24 h because there is no significant difference between
the number of KM-12c cells in the liver of CEA-pretreated
mice compared to HBSS-pretreated mice (data not shown).
Thus, the effect of CEA upon the production of experimental
metastases by weakly metastatic carcinoma cells is associated
with the early persistence of colorectal carcinoma cells within
the liver.
Discussion
The present study extends our earlier observations that CEA
injected intravenously into nude mice promotes the forma-
tion of experimental metastases by human colorectal car-
cinomas in nude mice (Hostetter et al., 1990a,b) and gives
insight into possible mechanisms. The distribution of CEA in
athymic nude mouse liver after intravenous injection is
similar to that previously reported in immunocompetent
mouse liver by Toth et al. (1982). Interestingly, although
murine Kupffer cells and hepatocytes contained CEA on
indirect immunoperoxidase staining of the liver within
30-60 min of the intravenous CEA injection, the CEA was
retricted to Kupffer cells at 4 h when the liver contained only
75 ng of CEA per mg cell protein. Kupffer cells contain
unique endocytic compartments in which material that is
poorly degraded is stored for extended periods (Kindberg et
al., 1991). This may account for the presence of CEA in
Kupffer cells at 4 h and possibly longer. CEA in human liver
adjacent to colorectal carcinoma metastases was also
regionally distributed in the intralobular or midzonal areas,
although not as symmetrically as in the nude mouse liver.
Concentrations greater than 10ngmlh' of CEA have been
observed in the bile that drains the livers of patients with
primary colon cancers who do not have clinical evidence of
metastasis (Yeatman et al., 1989). This finding combined
with our observation in a patient with metastases and an
elevated serum CEA suggests that the concentration of CEA
achieved in the liver is comparable to that used in vitro for
the adhesion of cells to CEA attached to a solid phase
(Hostetter et al., 1990b).
Our data demonstrate (1) that the propensity to form
metastases is dependent in part on the number of cells that
persist in the liver several hours after initial arrest and (2)
that CEA pretreatment increases the number of weakly
metastatic tumour cells present in the liver 4h after intra-
splenic injection. Fidler has shown that the technique of
using cells labelled endogenously with '25IdUdr identifies
intact cells within an organ (Fidler, 1970). Morikawa et al.
(1988b) and Hostetter et al. (1990b) demonstrated that the
percentage of cells in an organ 4 or more hours after
systemic injection is associated with the ability of those
tumour cells to produce metastases. Only 5% of the non-
metastatic HC 2998 human colon cancer cells were present in
the liver at 4 h which was much less than the approximately
20% of weakly metastatic KM-12c cells and over 40% of
highly metastatic mHC 1410 cells present in liver at that time
(Hostetter et al., 1990). Since the HC 2998 cells are not
present in blood or lungs and had the same percentage of
cells in the spleen as the metastatic cell lines at 4 h (data not
shown), it is likely that the nonmetastatic HC 2998 tumour
cells are lysed during the first few hours in the liver.
On entering the liver, tumour cells will be trapped in the
sinusoids (Weiss, 1990). The vast majority of these cells are
rapidly eliminated through various specific and nonspecific
defense mechanisms with the result that very few cells are left
to establish metastases. Nonetheless, some tumour cells sur-
vive in the hepatic microcirculation, leave the liver, and
successfully establish metastases elsewhere. For example,
both MIP-101 cells (Wagner et al., 1990) and Clone A cells
(TableII) produced lung metastases in CEA pretreated mice
that lacked liver metastases on microscopic examination.
Even though the process of metastasis is inefficient (Weiss,
1990), it stands to reason that the more viable tumour cells
that persist in the liver after an initial phase of trapping and
elimination, then the more metastases may be formed later
when these cells proliferate. This also suggests that CEA
pretreatment enhances the ability of tumour cells to resist the
various mechanisms of the host.
CEA may increase the persistence of weakly metastatic
carcinoma cell lines through several different mechanisms.
Hostetter et al. (1990b) have shown that KM-12c binds to
CEA attached to a solid phase. Thus, adhesion to CEA
attached to a surface may be an important mechanism. How-
ever, the other weakly metastatic cell lines that respond in
vivo to CEA pretreatment (MIP-101 and Clone A) do not
bind to CEA on a solid phase, although both the highly
metastatic HT-29 and nonmetastatic HC-2998 do bind in
vitro to CEA attached to a solid phase (Meterissian et al.,
1991). Microbeads coated with either albumin (Figure 2) or
with CEA (data not shown) were not preferentially retained
in the livers of mice that had received CEA intravenously.
Thus, while adhesion to cell surface CEA is an attractive
hypothesis and may be important for the promotion of
metastasis by one colorectal carcinoma line (KM-12c), it does
not explain the effects of CEA upon the two other weakly
metastatic lines.
CEA affects other aspects of the host-tumour relationship
apart from adhesion. We have shown previously that CEA
inhibits plaque forming cell responses to sheep erythrocytes
in mice and the production of antibodies to human tumour-
associated antigens by athymic nude mice (Hostetter et al.,
1990a). CEA also induced human T cells to release
immunosuppressive factors (Medoff et al., 1984) and to
directly inhibit lymphocyte proliferation (Hakim, 1984). It is
possible that the metastatic potential of MIP-101 and Clone
A may be enhanced by CEA-mediated inhibition of the
immune responses to nude mice. Nude mice make T-
independent responses that may support antibody-dependent
cell-mediated cytotoxicity and prevent the growth of experi-
mental metastases. CEA may inhibit the production of
antibodies that are deleterious to the establishment of liver
colonies by weakly metastatic cell lines. However, our data
suggest that CEA does not alter the lytic function of NK
cells by mouse spleen cells. It is doubtful that the cytostatic
or cytotoxic activity of unstimulated Kupffer cells in normal
nude mice will be effected by CEA pretreatment. Thus, it
seems unlikely that inhibition of natural host resistance
mechanisms participate in CEA-mediated enhancement of
experimental metastasis.
In summary, CEA injected intravenously into nude mice
facilitates the growth of tumour in liver and lung by three of
eight colorectal carcinoma lines. The cell lines enhanced by
CEA are all weakly metastatic and CEA increases the persist-
ence of these tumour cells in the liver. Since Kupffer cells in
rats and humans have both 35 and 80kDa receptors for
CEA (Thomas et al., 1991), CEA-expressing tumour cells
may bind to Kupffer cells using such a CEA:Kupffer cell470 J.M. JESSUP et al.
receptor interaction. CEA secreted by the primary tumour
may also enhance the metastasis of weakly metastatic cell
lines by occupying Kupffer cell receptors and binding with
CEA on tumour cells. While CEA-mediated adhesion is an
attractive hypothesis to explain the effect of CEA upon
metastasis, two of the CEA-enhancable cell lines (MIP-101
and Clone A) do not bind to purified CEA attached to a
solid phase (Meterissian et al., 1991). It is possible, therefore,
that some other adhesion molecule or molecules may be
involved in the persistence of tumour cells within liver, pos-
sibly through activation of Kupffer cells that metabolise
CEA. This activation may lead to cytokine release that
enhances expression of another adhesion receptor or ligand
to which the carcinoma cells may bind. Alternatively, CEA
may have some other, as yet undefined, action that promotes
the survival of tumour cells within the liver. Whatever
mechanism is operative, CEA is a product of tumour cells
that can facilitate the production of metastases within a
subset of colorectal carcinoma cell lines.
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